Monitoring for Adverse Events Post Marketing Approval of Drugs
International Journal of Allergy Medications
This brief communication provides information to those developing monitoring plans for serious adverse events (SAE’s) following regulatory approval of a new drug. In addition, we (1) illustrate how many patients would need to be treated in order to have high confidence of seeing at least 1 pre-specified SAE, (2) show that absence of proof of a SAE is not proof of absence of that SAE, and (3) identify statistical methodology that could be used for formal statistical monitoring of SAE’s.
Peace, Karl E., Macaulay Okwuokenye.
"Monitoring for Adverse Events Post Marketing Approval of Drugs."
International Journal of Allergy Medications, 1 (2).